Connect with us

BIOTECH

Q BioMed Inc (OTCMKTS:QBIO) Reports Licensing Deal For Drug Development

Published

on

Q BioMed Inc (OTCMKTS:QBIO) and ASDERA LLC reported a licensing deal that offers Q Biomed with the global rights to ASDERA’s ‘ASD-002’, which is being advanced to cure a rare pediatric nonverbal disorder. As per the agreement terms, the company has international rights to develop and market the drug in the rare pediatric disease industry.

The update

Among over 60,000 U.S. children who suffer from autism spectrum disorders every year, 20,000 lose their ability to speak. The numbers are not any different in Europe and this group relies on assisted living for the entire life.

Denis Corin, the CEO of Q Biomed, reported that considering the severity of this ailment, and the massive emotional toll on these kids and their families, their objective is to move the offering forward by utilizing all the regulatory tools accessible to them to expedite the development of this drug candidate.

The cost for assisted living along with the treatment in the United States alone can equal or surpass $10 million per person over a lifetime. The projected cost to the U.S. healthcare setup and lost productivity is anticipated at $200 billion each. As of now, there is no treatment available for this disorder. Genetic and behavioral testing, and EEG can identify a targeted population of kids in their second year of life that they consider would respond to this therapy.

The CEO of Q Biomed added that they are extremely thrilled about the prospect of ASD-002 and expectantly this will permit thousands of kids annually to advance speech and live productive and independent lives.

ASDERA’s objective is to focus on advancing targeted treatments for ailments where there is a high unmet need. The company is grateful to be associated with Q Biomed, which witnessed the potential of ASD-002 and are dedicated to confirming that ASD-002 reaches its planned target patient population.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement